BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease

Marta Barber; Ariadna Boloix; Alfonso Parrilla; Mariana Köber; Laia Avilés-Domínguez; Nora Ventosa; Lidia del Carmen Ramírez-Morales; Asunción Perez-Benavente; Antonio Gil-Moreno; Eva Colàs; Juan Morote; Miguel F. Segura; Olga Méndez; Anna Santamaria

doi:10.1002/ctm2.70285

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (4) : e70285 DOI: 10.1002/ctm2.70285

LETTER TO THE JOURNAL

BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease

Author information +

History +

PDF

Cite this article

Download citation ▾

Marta Barber, Ariadna Boloix, Alfonso Parrilla, Mariana Köber, Laia Avilés-Domínguez, Nora Ventosa, Lidia del Carmen Ramírez-Morales, Asunción Perez-Benavente, Antonio Gil-Moreno, Eva Colàs, Juan Morote, Miguel F. Segura, Olga Méndez, Anna Santamaria. BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease. Clinical and Translational Medicine, 2025, 15(4): e70285 DOI:10.1002/ctm2.70285

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71: 7-33.

[2]	Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016; 143(1): 3-15.

[3]	Parrilla A, Cirillo l, Thomas Y, et al. Mitotic entry: the interplay between Cdk1, Plk1 and Bora. Cell Cycle. 2016; 15(23): 3177-3182.

[4]	Wu J, Ivanov AI, Fisher PB, Fu Z. Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling. Elife. 2016; 5: e10734.

[5]	Shin SB, Jang HR, Xu R, Won JY, Yim H. Active PLK1-driven metastasis is amplified by TGF-β signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene. 2020; 39(4): 767-785.

[6]	García IA, Garro C, Fernandez E, Soria G. Therapeutic opportunities for PLK1 inhibitors: spotlight on BRCA1-deficiency and triple negative breast cancers. Mutat Res-Fund Mol Mech Mutagen. 2020; 821: 111693.

[7]	Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Transl Oncol. 2022; 16: 101332.

[8]	Parrilla A, Barber M, Majem B, et al. Aurora borealis (Bora), which promotes plk1 activation by aurora a, has an oncogenic role in ovarian cancer. Cancers. 2020; 12(4): 886.

[9]	Cheng S, Peng T, Zhu X, et al. BORA regulates cell proliferation and migration in bladder cancer. Cancer Cell Int. 2020; 20: 290.

[10]	Boloix A, Feiner-Gracia N, Köber M, et al. Engineering pH-sensitive stable nanovesicles for delivery of microRNA therapeutics. Small. 2022; 18: e2101959.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.